Editas Medicine

EDIT Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$2.67

+2.3% today

52W: $0.91 – $4.54

52W Low: $0.91 Position: 48.5% 52W High: $4.54

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

6.45x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$261.3M

Market Capitalization

Revenue Growth

-19.2%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-198.14%

Return on Equity

Beta

2.04

Market sensitivity

Short Interest

11.8%

% of float sold short

Avg. Volume

1,759,032

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

9 analysts

Avg. Price Target

$5.50

+105.99% upside

Target Range

$1.00 – $13.00

About the Company

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Geng

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 87 Exchange: NMS